Pneumothorax Treatment Market Share

North America Market Forecast

The pneumothorax treatment market in North America, is anticipated to hold the largest with a share of about ~28% by the end of 2036. The market growth in the region is also expected on account of the rising prevalence of pneumothorax due to the rise in chronic lung disease. Based on research, 2.28 million Canadians have asthma, placing the nation among those with the highest asthma prevalence globally. Furthermore, asthma and COPD are among the chronic lung diseases that affect approximately 34 million Americans. Moreover, high awareness of pneumothorax infection and easy availability of hospitals and medical centers in the region results, in more people likely to choose early diagnosis and treatment, fueling the market growth in the region. Additionally, the region's expanding healthcare sector and increasing expenditures in healthcare are also expected to propel the market's expansion in the years to come.

APAC Market Analysis

The Asia Pacific pneumothorax treatment market is estimated to be the second largest, registering a share of about ~21% by the end of 2036. The market’s expansion can be attributed majorly to the rising awareness about respiratory health and the burgeoning prevalence of lung-related diseases in the region. According to research, about 65 million individuals in India, and around 100 million individuals in China suffer from chronic obstructive pulmonary disease (COPD), which makes up nearly 25% of all COPD cases worldwide. This high incidence of lung-related diseases can be attributed to the unhealthy lifestyle, high pollution rates, and high number of smoking population in the region. In addition, the presence of major market players in developing countries like China India Japan, & the Philippines and government programs aimed at enhancing healthcare access across the region are anticipated to fuel pneumothorax treatment market expansion over the projected period.